Beam Therapeutics Inc. (BEAM) Stock
BEAM Key Statistics
About Beam Therapeutics Inc.
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
CEO: John Evans. Company website
BEAM — Frequently Asked Questions
What is the BEAM stock price today?
Beam Therapeutics Inc. (BEAM) trades at $24.95, up 1.13% on the day, as of Sep 20, 2026 14:59 UTC.
What is Beam Therapeutics Inc.'s market cap?
Beam Therapeutics Inc. has a market capitalisation of $2.57B, calculated from the live BEAM share price and shares outstanding.
What is the P/E ratio of BEAM?
BEAM has no meaningful price-to-earnings ratio: Beam Therapeutics Inc. lost $0.86 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Beam Therapeutics Inc. make?
Beam Therapeutics Inc. generated revenue of $156.04M over the trailing twelve months, which puts the stock at 16.45 times sales.
What is the 52-week range for BEAM?
BEAM has traded between $20.23 and $38.26 over the past 52 weeks, and the last price is 34.8% below that high.
Is Beam Therapeutics Inc. profitable?
No. Beam Therapeutics Inc. is loss-making, with a net margin of -54.75% over the trailing twelve months.
What is the analyst price target for BEAM?
Wall Street analysts rate BEAM Buy, with an average price target of $59.50, 138.5% above the current price.
What sector is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Beam Therapeutics Inc.?
John Evans is the chief executive of Beam Therapeutics Inc., which employs 540 people.
Where can I track BEAM in real time?
QFI Terminal shows BEAM with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See BEAM live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BEAM in Terminal See plans